TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $352
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.